Thrombotic and Atherogenetic Predisposition in Polyglobulic Donors

Area of Science:

• Hematology
• Genetics
• Clinical Diagnostics

Background:

• Secondary polyglobulia involves genetic hematological risks.
• Janus Kinase 2 (JAK2) mutation negativity can exclude autonomous myeloproliferative disease.
• Identifying key diagnostic markers is crucial for cost-effective patient management.

Purpose of the Study:

• To analyze genetic hematological risks associated with secondary polyglobulia.
• To identify significant markers for diagnosing high-risk patients.
• To differentiate essential diagnostic markers from complementary ones to reduce healthcare costs.

Main Methods:

• Selection of study subjects based on laboratory markers and clinical symptoms.
• Focus on thrombotic, immunological, metabolic, and cardiovascular risks.
• Analysis of Janus Kinase 2 (JAK2) mutation status.

Main Results:

• Groups with high mutation incidence showed higher risk for polycythemia vera.
• Different mutation combinations presented varied symptoms, complicating clear risk determination.
• Patients with less than 20% mutation incidence were deemed clinically insignificant for polycythemia vera testing, suggesting potential cost savings.
• The JAK V617F mutation is a critical marker for confirming or excluding polycythemia vera.

Conclusions:

• Effective clinical guidelines can be developed for diagnosing selected parameters with high sensitivity and specificity.
• The study provides a basis for optimizing diagnostic strategies for secondary polyglobulia and polycythemia vera.
• Focusing on specific mutations like JAK V617F can improve diagnostic accuracy and resource allocation.